vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%

vTv Therapeutics Inc VTVT has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here.

• As a part of the restructuring, the company will reduce its workforce by approximately 65%.
• The company also paused its development activities on HPP737, a PDE4 inhibitor for the treatment of psoriasis, while it evaluates strategic options.
• In September, vTv posted a favorable safety and tolerability profile for HPP737 in multiple ascending dose study in healthy volunteers. The company planned to start a 12-week Phase 2 trial of HPP737 in moderate to severe psoriasis in early 2022.
• TTP399 is an oral, liver-selective glucokinase activator that showed ~40% reduction in hypoglycemic episodes compared to placebo in its Phase 2 study and was granted FDA Breakthrough Therapy Designation.
• In October, the company announced positive results of its mechanistic study showing no increased risk of ketoacidosis. Zero hypoglycemic episodes occurred in the TTP399 arm, while four occurred on placebo.
• vTv will continue to support the development of its partnered programs.
• Price Action: VTVT shares closed lower by 0.88% at $1.13 on Monday.